Buried in the retatrutide TRIUMPH-4 data is a finding that flew under every weight-loss headline but should have landed directly in the lap of every man who squats heavy: knee osteoarthritis pain dropped by up to 73%. That is not a marginal improvement. That is the difference between training through grinding pain and training without it — the difference between modifying every leg session and actually loading the bar.
⚡ Key Takeaway
TRIUMPH-4 showed retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) alongside 28.7% body weight loss. For heavy men whose joint pain limits training, the weight-reduction pathway to pain relief may be as significant as the fat-loss outcome itself.
The TRIUMPH-4 Joint Pain Data
TRIUMPH-4 enrolled adults with obesity and knee osteoarthritis — a population that overlaps heavily with the big-man training demographic. Results showed 28.7% average weight loss at 68 weeks (the strongest Phase 3 obesity result when it reported in December 2025) with a concurrent reduction in knee osteoarthritis pain of up to 4.3 points on a standard pain scale, representing a 73.1% improvement.
The pain reduction is both weight-mediated and potentially direct. Every pound of body weight translates to roughly 4 pounds of force across the knee during walking and significantly more during squatting, lunging, or any loaded movement. Losing 28.7% of body weight reduces mechanical joint loading substantially. But the glucagon receptor activation in retatrutide may also produce anti-inflammatory effects independent of weight loss, which is an active area of investigation.
Why This Matters for Training
Joint pain is the primary reason men over 35 modify, reduce, or abandon lower-body training. Knee osteoarthritis affects roughly 10% of men over 40, and the rate climbs with BMI. For a 250-pound man who squats, the math is straightforward: his knees are absorbing over 1,000 pounds of force per step, and loaded squats multiply that further. Chronic pain in this population is not weakness — it is physics.
The training implications of reducing that pain by 73% are enormous. Men who have spent years working around knee pain — substituting leg press for squats, avoiding deep flexion, skipping plyometrics — could potentially return to full-range, progressive lower-body training. That training, in turn, produces the resistance signal that preserves muscle during the weight-loss phase, creating a positive feedback loop that addresses the primary muscle-loss concern with GLP-1 drugs.
The Practical Implication
If you are a heavy man with knee osteoarthritis that limits your training, retatrutide’s TRIUMPH-4 data suggests that aggressive weight loss through this pathway could restore joint function sufficiently to support the training that optimizes the body-composition outcome. That is a different proposition than simply “losing weight for your knees” — it is using weight loss to unlock training capacity that produces compounding returns across multiple domains.
The drug is not available yet (NDA expected Q4 2026, approval timeline late 2027 to Q1 2028). But the principle applies to any weight-loss intervention, pharmaceutical or otherwise: for men with joint-limited training, reducing mechanical load through weight loss can produce disproportionate returns by restoring access to movements that were previously too painful to perform effectively.